Comparison of efficacy and safety of neoadjuvant immunochemotherapy in young and elderly patients with IIA–IIIB non-small-cell lung cancer in real-world practice
For IIA-IIIB NSCLC, neoadjuvant immunochemotherapy in young patients can produce a higher percentage of patients with a pCR than in elderly patients. However, the survival benefits and incidence of AEs are similar in young and elderly patients.
Authors
- Jian Hu (ORCID: https://orcid.org/0000-0002-9494-9828)
- Wang Lv (ORCID: https://orcid.org/0009-0007-2014-0480)
- Pinghui Xia
- Yuhong Yang
- Xuhua Huang (ORCID: https://orcid.org/0000-0002-0022-2661)
- Yiqing Wang (ORCID: https://orcid.org/0000-0002-5626-8589)
- Jia-Cong Liu
Institutions
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University of Technology (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1186/s12890-024-03417-8
- Citations
- 2
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- National Key Research and Development Program of China